Journal
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
Volume 54, Issue 1, Pages 109-112Publisher
ELSEVIER TAIWAN
DOI: 10.1016/j.jmii.2020.09.003
Keywords
COVID-19; SARS-CoV-2; Pneumonia; Hydroxychloroquine; Azithromycin; Ciclesonide; Therapy; Reverse transcription-PCR
Categories
Ask authors/readers for more resources
The study reports the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.
No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy. Copyright (c) 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
